Scholars Central

Review articlePublished 23 Sep 2022

Genetic and Epigenetic Factors Involved in Cisplatin Resistance

Authors: Thomas Mathew

Molecular and Genetic Medicine

Volume 16 · Issue 9 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cisplatin (CDDP) is the drug of desire towards exclusive forms of most cancers. However, tumour cells can gather resistance to the harm as a result of cisplatin, producing genetic and epigenetic modifications that result in the era of resistance and the activation of intrinsic resistance mechanisms in most cancers cells. Among them, we will discover mutations, opportunity splicing, epigenetic-pushed expression modifications, or even post-translational changes of proteins. However, the molecular mechanisms with the aid of using which CDDP resistance develops aren't clean however are believed to be multi-factorial. This article highlights an outline of cisplatin, which incorporates motion mechanism, resistance and epigenetic elements concerned in cisplatin resistance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Molecular and Genetic Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMolecular and Genetic Medicine
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Thomas Mathew”